Q-omics provides the consensus-scored PPAN-P2RY11 profile across patient tissues and cancer cell-line models. PPAN-P2RY11 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PPAN-P2RY11 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PPAN-P2RY11 RNA expression shows 12,692 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCS, KIRC, and ACC as cancer lineages where PPAN-P2RY11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPAN-P2RY11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPAN-P2RY11 survival associations across molecular data types. PPAN-P2RY11 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPAN-P2RY11 RNA expression–survival associations across cancer types. High PPAN-P2RY11 expression shows unfavorable associations in UCS, ACC, KIRP and LUSC, but favorable associations in KIRC and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for PPAN-P2RY11 RNA expression.
This table summarizes PPAN-P2RY11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PPAN-P2RY11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPAN-P2RY11 shows lower tumor expression in KIRC, KICH, STAD and KIRP and higher tumor expression in BRCA and LUSC. The KIRC box plot shows higher PPAN-P2RY11 RNA expression in normal versus tumor tissue (log2 FC = −0.034, t-test p < 0.001).
This table shows molecular features associated with PPAN-P2RY11 in patient tissues and cancer cell lines. In patient samples, PPAN-P2RY11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPAN-P2RY11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUSC.
